Additional Supporting Information may be found in the online version of this article.

ART_33368_sm_SupplTable1.doc32KSupplementary Table 1
ART_33368_sm_SupplTable2.pdf72KSupplementary Table 2
ART_33368_sm_SupplFig1.tif28KSupplementary Figure 1. Model of dysregulated IFN pathways in CANDLE. Mutant i-proteasome induced IFN signaling abnormality is depicted in this tentative model. In response to a trigger such as infections, IFNs are produced which upregulate the expression of the i-proteasome to process the accumulating polyubiquitinated proteins. Defects in i-proteasomes caused by PSMB8 mutations results in increase of polyubiquitinated proteins and cell stress, which then trigger more IFN production, leading to a vicious cycle.
ART_33368_sm_SupplFig2.tif1483KSupplementary Figure 2. IFN signature under treatment with biologics in one CANDLE patient. Various treatments with biologics [TNF-alpha inhibition (adalimumab), IL-6 inhibition (tocilizumab), inhibition of the CD28/CD86 interaction (abatacept), or a calcineurin inhibitor (tacrolimus)] led to persistence of the interferon signature on microarray analysis. In red are upregulated genes compared to healthy age matched children.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.